Arrowhead Pharmaceuticals (ARWR) Cash from Operations (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 17 years of Cash from Operations data on file, last reported at 84442000.0 in Q1 2026.

• Quarterly Cash from Operations fell 81.65% year-over-year to 84442000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 36306000.0 (down 159.37% YoY) and the FY2025 annual result came in at 179552000.0, up 138.79% from the prior year.
• Cash from Operations grew to 84442000.0 in Q1 2026, from 13481000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 460053000.0 in Q1 2025 to a low of 154720000.0 in Q2 2025.
• A 5-year average of 24358176.47 and a median of 68737000.0 in 2022 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2024 — Cash from Operations slumped 455.51% — and 2025, when it jumped 598.02%.
• Tracing ARWR's Cash from Operations over 5 years: stood at 75516000.0 in 2022, then plunged by 56.05% to 117840000.0 in 2023, then dropped by 24.13% to 146272000.0 in 2024, then jumped by 109.22% to 13481000.0 in 2025, then jumped by 526.38% to 84442000.0 in 2026.
• The last three Cash from Operations figures came in at 84442000.0 (Q1 2026), 13481000.0 (Q4 2025), and 20491000.0 (Q3 2025), per Business Quant data.